Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Madrigal

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Jun 25, 2021 1:38pm

93 Views

Post# 33451212

RE:RE:Madrigal

so this was the add-on trial with NAFLD patients only. I think they wanted to test both non-invasive diagnostics as well as get a better read on a lot of the metabolic syndrome changes in that cohort. Maybe as a way to think about earlier usage or just to bolster it in the NASH part of the trial (?). In either case showing good numbers for 52 weeks on a fat buster approach is a good sign for what THTX are looking to do. Long treatment cycle upstream to get liver readings back to healthy signals. I'm not sure this Madrigal trial really moves the needle much for them on the actual NASH side other than it's all positive, but in early stages. That could account for the muted reaction.

scarlet1967 wrote:

“Study highlights the potential use of non-invasive assessments to diagnose NASH and monitor individual patient response to resmetirom treatment.”

Apart from their results one key point is the non-invasive diagnostics seems to be reliable.

If the agencies recognize that fact and accept non-invasive diagnosis it will make future trials much smoother. ATM I believe phase2b and 3 require biopsies.

https://www.globenewswire.com/news-release/2021/06/25/2253378/0/en/Madrigal-Pharmaceuticals-Announces-Presentation-of-Positive-Clinical-Data-of-Resmetirom-from-Open-Label-Portion-of-Ongoing-Phase-3-Clinical-Trial-MAESTRO-NAFLD-1-at-The-Internation.html

palinc2000 wrote: Madrigal Pharma announces “positive” data from NASH trial
https://seekingalpha.com/news/3710196-madrigal-pharma-announces-positive-data-from-nash-trial